Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system
- PMID: 35092540
- DOI: 10.1007/s10928-021-09800-w
Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system
Abstract
In this manuscript, we present a translational physiologically-based pharmacokinetic (PBPK) model to characterize receptor-mediated transcytosis (RMT) of anti-transferrin receptor (TfR) monoclonal antibodies (mAbs) in the central nervous system (CNS). The model accounts for the state-of-the-art knowledge of the brain's anatomy and physiology, and physiological parameters were fixed according to different species. By estimating a few parameters associated with the TfR concentration, the TfR turnover, and the internalization rate, the model simultaneously characterizes plasma, whole brain, interstitial fluid (ISF), and cerebrospinal fluid (CSF) PK of unbound and bound anti-TfR mAbs with different binding affinities in mice, rats, and monkeys obtained from various literature sources within a threefold prediction error. The final PBPK model was validated using external anti-TfR mAb PK data in mice and monkeys with different affinities and doses. The simulation reasonably predicted plasma and brain PK of monovalent/bivalent anti-TfR mAbs within a threefold prediction error and characterized a bell-shaped relationship between the brain ISF/plasma AUC ratio and the KD value. Although further refinements of the PBPK model and clinical validation are required, this PBPK model may provide physiologically-based translation of CNS disposition of anti-TfR mAbs by accounting for the physiological difference of the endogenous RMT system among different species. The PBPK model may also guide selection of other endogenous receptors, lead optimization, and clinical development of novel CNS-targeted mAbs.
Keywords: Brain; Monoclonal antibody; PBPK model; Pharmacokinetics; Receptor-mediated transcytosis; TfR.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
A translational platform PBPK model for antibody disposition in the brain.J Pharmacokinet Pharmacodyn. 2019 Aug;46(4):319-338. doi: 10.1007/s10928-019-09641-8. Epub 2019 May 21. J Pharmacokinet Pharmacodyn. 2019. PMID: 31115858 Free PMC article.
-
Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis.MAbs. 2021 Jan-Dec;13(1):1874121. doi: 10.1080/19420862.2021.1874121. MAbs. 2021. PMID: 33499723 Free PMC article.
-
Advanced translational PBPK model for transferrin receptor-mediated drug delivery to the brain.J Control Release. 2023 May;357:379-393. doi: 10.1016/j.jconrel.2023.04.012. Epub 2023 Apr 12. J Control Release. 2023. PMID: 37031741
-
Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.Int J Mol Sci. 2022 Oct 22;23(21):12754. doi: 10.3390/ijms232112754. Int J Mol Sci. 2022. PMID: 36361546 Free PMC article. Review.
-
Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis.Chem Pharm Bull (Tokyo). 2020;68(4):316-325. doi: 10.1248/cpb.c19-00854. Chem Pharm Bull (Tokyo). 2020. PMID: 32238649 Review.
Cited by
-
Modeling Blood-Brain Barrier Permeability to Solutes and Drugs In Vivo.Pharmaceutics. 2022 Aug 15;14(8):1696. doi: 10.3390/pharmaceutics14081696. Pharmaceutics. 2022. PMID: 36015323 Free PMC article. Review.
-
Physiologically Based Pharmacokinetic Modeling to Characterize the Effect of Molecular Charge on Whole-Body Disposition of Monoclonal Antibodies.AAPS J. 2023 Apr 28;25(3):48. doi: 10.1208/s12248-023-00812-7. AAPS J. 2023. PMID: 37118220
-
Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases.J Pharmacokinet Pharmacodyn. 2024 Oct;51(5):563-573. doi: 10.1007/s10928-023-09876-6. Epub 2023 Jul 28. J Pharmacokinet Pharmacodyn. 2024. PMID: 37505397 Review.
-
Investigation of Antibody Pharmacokinetics in the Brain Following Intra-CNS Administration and Development of PBPK Model to Characterize the Data.AAPS J. 2024 Mar 5;26(2):29. doi: 10.1208/s12248-024-00898-7. AAPS J. 2024. PMID: 38443635
-
Treatment of Neuronopathic Mucopolysaccharidoses with Blood-Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis.Pharmaceutics. 2022 Jun 11;14(6):1240. doi: 10.3390/pharmaceutics14061240. Pharmaceutics. 2022. PMID: 35745811 Free PMC article. Review.
References
-
- Wang Q, Delva L, Weinreb PH, Pepinsky RB, Graham D, Veizaj E, Cheung AE, Chen W, Nestorov I, Rohde E, Caputo R, Kuesters GM, Bohnert T, Gan LS (2018) Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration. Fluids Barriers CNS 15(1):10 - PubMed - PMC - DOI
-
- Yadav DB, Maloney JA, Wildsmith KR, Fuji RN, Meilandt WJ, Solanoy H, Lu Y, Peng K, Wilson B, Chan P, Gadkar K, Kosky A, Goo M, Daugherty A, Couch JA, Keene T, Hayes K, Nikolas LJ, Lane D, Switzer R, Adams E, Watts RJ, Scearce-Levie K, Prabhu S, Shafer L, Thakker DR, Hildebrand K, Atwal JK (2017) Widespread brain distribution and activity following icv infusion of anti-beta-secretase (BACE1) in nonhuman primates. Br J Pharmacol 174(22):4173–4185 - PubMed - PMC - DOI
-
- Pizzo ME, Wolak DJ, Kumar NN, Brunette E, Brunnquell CL, Hannocks MJ, Abbott NJ, Meyerand ME, Sorokin L, Stanimirovic DB, Thorne RG (2018) Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery. J Physiol 596(3):445–475 - PubMed - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources